Dehydrovariabilin

Dehydrovariabilin

SCHEMBL13657398

COc1ccc2c(c1)OCc1c-2oc2cc(OC)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 1.00
KDM4E B2RXH2 8/20 1.00
CYP3A4 P08684 7/20 1.00
KMT2A Q03164 5/20 1.00
MEN1 O00255 4/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
USP2 O75604 2/20 1.00
ALOX15 P16050 2/20 1.00
PGR P06401 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 8/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
POLB P06746 1/20 0.42
STAT1 P42224 1/20 0.42
HPGD P15428 4/20 0.42
HSD17B10 Q99714 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydrovariabilin SCHEMBL31368572 1.00 MAPT (1.00) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL5108163 0.82 MAPT (0.69) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL31464865 0.75 KDM4E (0.60) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL13891899 0.69 MAPT (0.52) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL68899 0.69 MAPT (0.59) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL31689707 0.69 MAPT (0.59) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL7097279 0.69 KDM4E (0.69) MAPTKDM4ESMN1; SMN2CYP2D6ALDH1A1
SCHEMBL3925870 0.68 ESRRB (0.65) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL29747120 0.68 MEN1 (0.51) MAPTKDM4ECYP3A4KMT2AMEN1
SCHEMBL3144077 0.67 MAPT (0.52) MAPTKDM4ECYP3A4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9345694-B2 Compounds for enhancing arginase activity and methods of using same CORNELL RESEARCH FOUNDATION, INC. (US) 2016-05-24 US disclosed
US-20130245070-A1 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) 2013-09-19 US disclosed
US-20090253782-A1 Compounds for Enhancing Arginase Activity and Methods of USe Thereof CORNELL RESEARCH FOUNDATION, INC. 2009-10-08 US disclosed
US-20090208432-A1 AH Receptor Antagonists SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
US-20090208432-A1 AH Receptor Antagonists SYMRISE GMBH & CO., KG (DE) 2009-08-20 US disclosed
WO-2007128725-A1 6H-BENZOFURO[3,2-C] [1]BENZOPYRAN AND [2] BENZOPYRANO [4,3-B] [1]BENZOPYRAN DERIVATIVES AND WOOD EXTRACTS OF THESE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) ANTAGONISTS FOR THE PREVENTION OF UV-B INDUCED SKIN DAMAGE SYMRISE GMBH & CO. KG (DE) 2007-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208432-A1 AH Receptor Antagonists AHR, ARNT, HCAR1 MAPT 4785/4885KDM4E 2085/4885CYP3A4 337/4885
US-20130245070-A1 COMPOUNDS FOR ENHANCING ARGINASE ACTIVITY AND METHODS OF USING SAME ARG2, ARG1, OTC MAPT 3632/4885KDM4E 1426/4885CYP3A4 3922/4885
US-20090253782-A1 Compounds for Enhancing Arginase Activity and Methods of USe Thereof ARG2, ARG1, OTC MAPT 3726/4885KDM4E 1521/4885CYP3A4 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.